Wall Street Zen Downgrades Radiopharm Theranostics (NASDAQ:RADX) to Strong Sell

Radiopharm Theranostics (NASDAQ:RADX) was downgraded by equities research analysts at Wall Street Zen to a “strong sell” rating in a research note issued on Friday.

RADX has been the subject of a number of other reports. B. Riley reiterated a “buy” rating and set a $16.00 price target (up from $13.00) on shares of Radiopharm Theranostics in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Radiopharm Theranostics presently has an average rating of “Buy” and a consensus price target of $15.33.

Radiopharm Theranostics Trading Down 2.4%

Shares of RADX opened at $4.93 on Friday. Radiopharm Theranostics has a 52-week low of $3.50 and a 52-week high of $16.25. The company has a 50-day simple moving average of $5.02 and a 200-day simple moving average of $5.33.

Hedge Funds Weigh In On Radiopharm Theranostics

A hedge fund recently raised its stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. lifted its holdings in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,000 shares of the company’s stock after buying an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned about 0.20% of Radiopharm Theranostics worth $88,000 as of its most recent SEC filing.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.